Cargando…

Impact of a publicly-funded pharmacare program policy on benzodiazepine dispensing among children and youth: a population-based natural experiment

BACKGROUND: In January 2018, the Government of Ontario, Canada, initiated a universal pharmacare program (OHIP+) for all individuals aged 24 years and younger. In April 2019, the program was amended to cover only children and youth without private insurance. Because benzodiazepines are commonly pres...

Descripción completa

Detalles Bibliográficos
Autores principales:	Antoniou, Tony, McCormack, Daniel, Kitchen, Sophie, Pajer, Kathleen, Gardner, William, Lunsky, Yona, Penner, Melanie, Tadrous, Mina, Mamdani, Muhammad, Juurlink, David N., Gomes, Tara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10585894/ https://www.ncbi.nlm.nih.gov/pubmed/37858122 http://dx.doi.org/10.1186/s12887-023-04331-4

Ejemplares similares

Impact of a Publicly-Funded Pharmacare Program on Prescription Stimulant use Among Children and Youth: A Population-Based Observational Natural Experiment
por: Antoniou, Tony, et al.
Publicado: (2023)

Geographic variation and sociodemographic correlates of prescription psychotropic drug use among children and youth in Ontario, Canada: a population-based study
por: Antoniou, Tony, et al.
Publicado: (2023)

Adherence to antipsychotic laboratory monitoring guidelines in children and youth: a population-based study
por: Antoniou, Tony, et al.
Publicado: (2023)

The Risk of Ventricular Dysrhythmia or Sudden Death in Patients Receiving Serotonin Reuptake Inhibitors With Methadone: A Population-Based Study
por: Antoniou, Tony, et al.
Publicado: (2022)

Impact of a Publicly Funded Herpes Zoster Immunization Program on the Burden of Disease in Ontario, Canada: A Population-based Study
por: Martins, Diana, et al.
Publicado: (2020)

Interprovincial Variation of Psychotropic Prescriptions Dispensed to Older Canadian Adults
por: Black, Cody D., et al.
Publicado: (2018)

Varenicline and Risk of Self-Harm: A Nested Case-Control Study
por: Tadrous, Mina, et al.
Publicado: (2016)

Association Between Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, and Suicide
por: Mamdani, Muhammad, et al.
Publicado: (2019)

The uptake of the pharmacy-dispensed naloxone kit program in Ontario: A population-based study
por: Choremis, Beatrice, et al.
Publicado: (2019)

Understanding the Battle for Universal Pharmacare in Canada Comment on "Universal Pharmacare in Canada"
por: Gagnon, Marc-André
Publicado: (2020)

Impact of policy changes on the provision of naloxone by pharmacies in Ontario, Canada: a population‐based time–series analysis
por: Antoniou, Tony, et al.
Publicado: (2021)

Impact of the COVID-19 Controlled Drugs and Substances Act exemption on pharmacist prescribing of opioids, benzodiazepines and stimulants in Ontario: A cross-sectional time-series analysis
por: Chang, Ann, et al.
Publicado: (2022)

Publicly Funded Oral Chronic Hepatitis B Treatment Patterns in Ontario over 16 Years: An Ecologic Study
por: Tadrous, Mina, et al.
Publicado: (2018)

Duration of use and outcomes among people with opioid use disorder initiating methadone and buprenorphine in Ontario: a population‐based propensity‐score matched cohort study
por: Gomes, Tara, et al.
Publicado: (2022)

Impact of changes in opioid funding and clinical policies on rapid tapering of opioids in Ontario, Canada
por: Martins, Diana, et al.
Publicado: (2022)

Projected impact of biosimilar substitution policies on drug use and costs in Ontario, Canada: a cross-sectional time series analysis
por: Gomes, Tara, et al.
Publicado: (2021)

A population-based study of the risk of osteoporosis and fracture with dutasteride and finasteride
por: Antoniou, Tony, et al.
Publicado: (2018)

The Challenges of Canadian Pharmacare Are More Complicated Than Acknowledged Comment on "Universal Pharmacare in Canada"
por: Acri née Lybecker, Kristina M. L.
Publicado: (2020)

The epidemiology of benzodiazepine-related toxicity in Ontario, Canada: a population-based descriptive study
por: Campbell, Tonya J., et al.
Publicado: (2023)

Effect of listing strategies on utilization of antitumor necrosis factor biologics infliximab and etanercept: a cross-sectional analysis from Ontario, Canada
por: Fenna, Jennifer, et al.
Publicado: (2021)

The Burden of Opioid-Related Mortality in the United States
por: Gomes, Tara, et al.
Publicado: (2018)

Antipsychotic Use With and Without Comorbid Psychiatric Diagnosis Among Adults with Intellectual and Developmental Disabilities
por: Lunsky, Yona, et al.
Publicado: (2017)

Antipsychotic initiation among adults with intellectual and developmental disabilities in Ontario: a population-based cohort study
por: Gomes, Tara, et al.
Publicado: (2019)

The impact of proposed regulatory changes and rescheduling on low-dose codeine purchasing in Canada: a time-series analysis
por: Boone, Charlotte G., et al.
Publicado: (2021)

Separated at Birth: The Politics of Pharmacare for All in Canada and Medicare for All in the United States Comment on "Universal Pharmacare in Canada"
por: Tuohy, Carolyn Hughes
Publicado: (2020)

Trends in Opioid Toxicity–Related Deaths in the US Before and After the Start of the COVID-19 Pandemic, 2011-2021
por: Gomes, Tara, et al.
Publicado: (2023)

Introduction of publicly funded pharmacare and socioeconomic disparities in glycemic management in children and youth with type 1 diabetes in Ontario, Canada: a population-based trend analysis
por: Giruparajah, Mohana, et al.
Publicado: (2022)

National Pharmacare in Canada: Equality or Equity, Accessibility or Affordability Comment on "Universal Pharmacare in Canada: A Prescription for Equity in Healthcare"
por: Rawson, Nigel S. B.
Publicado: (2020)

Prior Authorization and Canadian Public Utilization of Direct-Acting Oral Anticoagulants
por: Gao, Lulu, et al.
Publicado: (2017)

Measuring the Burden of Opioid-related Mortality in Ontario, Canada
por: Gomes, Tara, et al.
Publicado: (2018)

The Impact of Drug Reimbursement Policy on Rates of Testosterone Replacement Therapy among Older Men
por: Piszczek, Jolanta, et al.
Publicado: (2014)

Reformulation of controlled-release oxycodone and pharmacy dispensing patterns near the US–Canada border
por: Gomes, Tara, et al.
Publicado: (2012)

Assessment of Stimulant Use and Cardiovascular Event Risks Among Older Adults
por: Tadrous, Mina, et al.
Publicado: (2021)

Clinical outcomes and health care costs among people entering a safer opioid supply program in Ontario
por: Gomes, Tara, et al.
Publicado: (2022)

Contributions of prescribed and non-prescribed opioids to opioid related deaths: population based cohort study in Ontario, Canada
por: Gomes, Tara, et al.
Publicado: (2018)

Impact of delisting high‐strength opioid formulations from a public drug benefit formulary on opioid utilization in Ontario, Canada
por: Martins, Diana, et al.
Publicado: (2019)

Universal Pharmacare in Canada: A Prescription for Equity in Healthcare
por: Hajizadeh, Mohammad, et al.
Publicado: (2019)

Clinical indications associated with opioid initiation for pain management in Ontario, Canada: a population-based cohort study
por: Pasricha, Sachin V., et al.
Publicado: (2018)

Changing patterns of opioid initiation for pain management in Ontario, Canada: A population-based cross-sectional study
por: Gomes, Tara, et al.
Publicado: (2022)

A comparison of opioids and benzodiazepines dispensing in Australia
por: Islam, M. Mofizul, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_pmlohp85hudna1lilq4bomgn55